Before You Arrive

Before-You-ArriveAt Hope Cancer Care of Nevada, we understand that the anticipation of your first visit can be filled with anxiety. Rest assured, you are about to meet a team of medical professionals dedicated to your recovery. Each team member at Hope Cancer Care of Nevada is 100 percent committed to keeping you informed and at ease during this moment in your life.

Before you arrive, we recommend taking a virtual walkthrough of our facilities in Las Vegas and Pahrump—we believe you’ll like what you’ll see. Take note of the serene atmosphere filled with the luxuries of modern, high-end living. Plush furniture, flat screen TVs, ambient lighting and an overall décor designed to wrap you in comfort. There are also features you can’t see but you will definitely feel them once you arrive, such as our aromatherapy system.

We invite you to bring a list of any questions you may have. Our friendly staff and your personal oncologist are here to answer them before, during and long after your graduation. If you are still feeling a bit hesitant, get to know the Hope Cancer Care of Nevada team by viewing their “bios”. You’ll find that they are highly trained and highly personable individuals who can’t wait to welcome you into our family.

At Hope Cancer Care of Nevada, our patients are just that—family. As you progress through your current journey, we want you to know that you are not alone. Graduates of the Hope cancer treatment program are our biggest advocates, and are eager to share their personal insights, experiences and thoughts regarding their time at Hope Cancer Care of Nevada. Listen to what they have to say by reading their testimonials.

We look forward to personally getting to know you while assisting you in achieving a steady recovery at Hope Cancer Care of Nevada.

slide_0

Norman Sharpless sworn in as director of the National Cancer Institute

10/18/17

Norman E. “Ned” Sharpless, M.D., becomes the 15th director of the National Cancer Institute (NCI). He comes to NCI from the University of North Carolina School of Medicine, where he was director of the Lineberger Comprehensive Cancer Center. …read more … Read More


Behind the numbers: cancers associated with obesity

10/03/17

By David Sampson A report out today had a lot of us scratching our heads, when it said that about 630,000 people in the U.S. were diagnosed with a cancer associated with overweight and obesity in 2014. That sounds awfully … Read More


NCI-funded TMIST study compares 2-D and 3-D mammography for finding breast cancers

09/26/17

TMIST, the first randomized trial comparing two types of digital mammography for breast cancer screening, is enrolling participants. Developed by ECOG-ACRIN and NCI, the trial is comparing 2-D and 3-D mammography for finding breast cancers. …read more Source:: Cancer


NCI’s Douglas R. Lowy and John T. Schiller to receive 2017 Lasker Award

09/06/17

Dr. Douglas R. Lowy and Dr. John T. Schiller of the National Cancer Institute receive the 2017 Lasker-DeBakey Clinical Medical Research Award for their significant research leading to the development of HPV vaccines. …read more Source:: Cancer


New Analysis Confirms Suspected Bias of Large U.S. Prostate Screening Study

09/05/17

By David Sampson A new paper appearing in Annals of Internal Medicine used simulation modeling to try to correct for a known bias in a notable U.S. trial of prostate cancer screening, called PLCO. That study along with a large … Read More


NCI study identifies essential genes for cancer immunotherapy

08/07/17

A new NCI study identifies genes in cancer cells that are necessary for them to be killed by T cells, and therefore could be partially responsible for why immunotherapy doesn’t work in some patients. …read more Source:: Cancer


NCI study shows feasibility of cancer screening protocol for patients with Li-Fraumeni syndrome

08/03/17

A new NCI study demonstrates the feasibility of a comprehensive screening protocol for patients with Li-Fraumeni syndrome, a rare inherited disorder that leads to a higher risk of developing certain cancers. …read more Source:: Cancer


NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers

07/24/17

The nationwide precision medicine trial will enroll children and adolescents with advanced cancers that haven’t responded to standard therapy to explore treatments targeted at specific genetic mutations. …read more Source:: Cancer


TCGA study of liver cancer reveals potential targets for therapy

06/15/17

Only two drugs are FDA-approved for liver cancer. This study of hepatocellular carcinoma found genetic alterations in tumors—including mutations in tumor-suppressing genes and high expression of immune checkpoint genes—that could be targets for drugs that already exist. …read more Source:: … Read More


Don’t Fry Day: Getting Sunscreen Right

05/25/17

By David Sampson Despite increased awareness about the dangers of ultraviolet (UV) radiation, melanoma rates continue to rise in the United States. For “Don’t Fry Day” on May 26, the American Cancer Society is cautioning that many people may be … Read More